Organon, Shanghai Henlius Biotech Launch Denosumab Biosimilars in Canada

MT Newswires Live

06/23

Organon's (OGN) Canada unit and Shanghai Henlius Biotech launched Bildyos and Tuzemty injections in Canada, the companies said Tuesday.

The products, denosumab biosimilars to Prolia and Xgeva, are approved for all indications of the reference medicines and are used to treat osteoporosis and bone conditions linked to cancer, according to the companies.

The launches expand Organon's biosimilar portfolio in Canada and follow a 2022 licensing and supply agreement with Henlius that granted Organon exclusive commercialization rights for the products outside China, the companies said.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2645838996"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645838996\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645838996?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 18:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645838996","market":"hk","top_or_hot":-1,"title":"Organon, Shanghai Henlius Biotech Launch Denosumab Biosimilars in Canada","media":"MT Newswires Live","content":"<html><body><p> Organon's (OGN) Canada unit and <a href=\"https://laohu8.com/S/SGBCF\">Shanghai Henlius Biotech</a> launched Bildyos and Tuzemty injections in Canada, the companies said Tuesday.</p><p>The products, denosumab biosimilars to Prolia and Xgeva, are approved for all indications of the reference medicines and are used to treat osteoporosis and bone conditions linked to cancer, according to the companies.</p><p>The launches expand Organon's biosimilar portfolio in Canada and follow a 2022 licensing and supply agreement with Henlius that granted Organon exclusive commercialization rights for the products outside China, the companies said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Organon, Shanghai Henlius Biotech Launch Denosumab Biosimilars in Canada</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrganon, Shanghai Henlius Biotech Launch Denosumab Biosimilars in Canada\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-06-23 18:57</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Organon's (OGN) Canada unit and <a href=\"https://laohu8.com/S/SGBCF\">Shanghai Henlius Biotech</a> launched Bildyos and Tuzemty injections in Canada, the companies said Tuesday.</p><p>The products, denosumab biosimilars to Prolia and Xgeva, are approved for all indications of the reference medicines and are used to treat osteoporosis and bone conditions linked to cancer, according to the companies.</p><p>The launches expand Organon's biosimilar portfolio in Canada and follow a 2022 licensing and supply agreement with Henlius that granted Organon exclusive commercialization rights for the products outside China, the companies said.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XBI","symbol_name":"SPDR S&P Biotech ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2645838996","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645838996","pubTimestamp":1782212271,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Organon's  Canada unit and Shanghai Henlius Biotech launched Bildyos and Tuzemty injections in Canada, the companies said Tuesday.The products, denosumab biosimilars to Prolia and Xgeva, are approved for all indications of the reference medicines and are used to treat osteoporosis and bone conditions linked to cancer, according to the companies.The launches expand Organon's biosimilar portfolio in Canada and follow a 2022 licensing and supply agreement with Henlius that granted Organon exclusive commercialization rights for the products outside China, the companies said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XBI":"SPDR S&P Biotech ETF","BK4585":"ETF&股票定投概念","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","OGN":"Organon & Co","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","BK4559":"巴菲特持仓","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","BK4581":"高盛持仓","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4007":"制药","BK4588":"碎股"},"translate_title":"Organon、上海复宏汉霖生物在加拿大推出Denosumab生物仿制药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":1.5,"OGN":1},"content_text":"Organon's (OGN) Canada unit and Shanghai Henlius Biotech launched Bildyos and Tuzemty injections in Canada, the companies said Tuesday.The products, denosumab biosimilars to Prolia and Xgeva, are approved for all indications of the reference medicines and are used to treat osteoporosis and bone conditions linked to cancer, according to the companies.The launches expand Organon's biosimilar portfolio in Canada and follow a 2022 licensing and supply agreement with Henlius that granted Organon exclusive commercialization rights for the products outside China, the companies said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}